Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.
Fangda assists Brattea in completing its high-value series-D financing
2024 / 04 / 24
READ MORE
2026 / 02 / 14
Fangda Advises BPS on CSRC Registration Approval for Major Asset Restructuring
2026 / 02 / 12
Fangda Advises GDS on the Successful Issuance of USD 300 million in Series B Convertible Preferred Shares
2026 / 02 / 09
Fangda Advises Zoomlion on the First-Ever Issuance of Special Mandate H-Share Convertible Bonds by an A+H Listed Company
2026 / 02 / 06
Fangda Advises Muyuan on Its Successful HKEX Listing and H-Share Offering
2026 / 02 / 03
Fangda Advises XtalPi on HKD 2.866 billion Convertible Bond Issuance
